Moderna Inc (MRNA)vsNanoViricides Inc (NNVC)
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
NNVC
NanoViricides Inc
$1.02
0.00%
HEALTHCARE · Cap: $28.59M
Smart Verdict
WallStSmart Research — data-driven comparison
NNVC leads profitability with a 0.0% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).
MRNA
Avoid21
out of 100
Grade: F
NNVC
Avoid18
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Intrinsic value data unavailable for NNVC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : NNVC
The strongest argument for NNVC centers on Price/Book.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : NNVC
The primary concerns for NNVC are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while NNVC is a value play — different risk/reward profiles.
NNVC carries more volatility with a beta of 1.66 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
NNVC generates stronger free cash flow (-2M), providing more financial flexibility.
Bottom Line
MRNA scores higher overall (21/100 vs 18/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
NanoViricides Inc
HEALTHCARE · BIOTECHNOLOGY · USA
NanoViricides, Inc., a nanobiopharmaceutical company, discovers, develops and markets drugs for the treatment of viral infections. The company is headquartered in Shelton, Connecticut.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?